MacroGenics Inc

Change company Symbol lookup

Select an option...

MGNX MacroGenics Inc

CBZ CBIZ Inc

PSEC Prospect Capital Corp

SPEC Spectralcast Inc

RC Ready Capital Corp

GNK Genco Shipping & Trading Ltd

NVOS Novo Integrated Sciences Inc

PDRDF Pernod Ricard SA

RKDA Arcadia Biosciences Inc

BBVA Banco Bilbao Vizcaya Argentaria SA

Go

MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.